Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
(Date:12/25/2014)... 25, 2014 The report “Service Quality ... Type & Provider Type - Global Advancements, Worldwide Forecasts ... an in-depth analysis and forecasting of revenues. , ... 221 pages and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... . From the motion sensor to the ... are used whose functioning is based on smallest structures of ... millimetres. These micro and nano structures must be manufactured and ... the overall system will function smoothly. Thereby, details are important ...
... OmniGuide, Inc., the developer of the first and only ... technology, today announced the results of a pre-clinical study ... in neurosurgery. In the study, surgeons from the Barrow ... in live brain tissue with fiber delivered CO2 laser ...
... HARBIN, China, July 6 /PRNewswire-Asia-FirstCall/ -- China ... a vertically integrated grower,developer, manufacturer and marketer ... that it has retained the services of ... China Kangtai will be,available through the Hawk ...
Cached Biology Technology:Nano measurement in the third dimension 2New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue 2New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue 3China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services 2China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services 3
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of insulin ... other mental capabilities in adults with mild cognitive impairment ... led by researchers at Wake Forest Baptist Medical Center. ... with amnesic mild cognitive impairment (MCI) or mild to ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... WEST LAFAYETTE, Ind. - A new technology enabling ... could make possible super-accurate and precise sensors for ... The innovation might enable researchers to create a ... hazardous solid or gaseous substances, as well as ...
... 10, 2010 Eurofins MWG Operon, international market leader and ... Limited (RCUK SSC Ltd) have signed a three year contract ... long term contract builds on the relationship developed as a ... previous four years. RCUK SSC Ltd has been ...
... usually don,t die from a heart attack. But the damage ... to congestive heart failure, the most common cause of death ... for achieving what the body can,t do: mending broken hearts. ... a scaffold that supports the growth and integration of stem ...
Cached Biology News:Innovation could bring super-accurate sensors, crime forensics 2Innovation could bring super-accurate sensors, crime forensics 3Innovation could bring super-accurate sensors, crime forensics 4A strategy to fix a broken heart 2A strategy to fix a broken heart 3
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... called a ?cap? is present on ... mRNAs and many viral RNAs. Substitution ... of the GTP present in an ... the synthesis of transcripts with a ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Biology Products: